Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -534.43% is 649% below its 5-year average of -71.30%, near the low end of its 5-year range (-534.43%–-44.99%).
464.43% below its 12-month average of -94.69%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -498.48%.
RETURN ON ASSETS (ROA)
-534.43%
RETURN ON ASSETS (ROA) AVG TTM
-94.69%
RETURN ON ASSETS (ROA) AVG 3Y
-82.47%
RETURN ON ASSETS (ROA) AVG 5Y
-71.30%
RETURN ON ASSETS (ROA) AVG 10Y
-61.19%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-464.43%
CURRENT VS 3Y AVG
-548.01%
CURRENT VS 5Y AVG
-649.50%
CURRENT VS 10Y AVG
-773.34%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-24.95%
median of 438 covered companies
CURRENT VS SECTOR MEDIAN
-2042.00%
vs the sector median at left
Cue Biopharma, Inc.
Market Cap
$176.96M
Return on Assets (ROA)
-534.43%
TTM Avg
-94.69%
3Y Avg
-82.47%
5Y Avg
-71.30%
Market Cap
$179.70M
Return on Assets (ROA)
-17.38%
TTM Avg
-167.34%
3Y Avg
-136.62%
5Y Avg
-286.91%
Market Cap
$174.17M
Return on Assets (ROA)
-41.88%
TTM Avg
-12.18%
3Y Avg
-27.40%
5Y Avg
-32.78%
Market Cap
$173.04M
Return on Assets (ROA)
-68.50%
TTM Avg
-29.78%
3Y Avg
-39.51%
5Y Avg
-30.76%
Market Cap
$172.99M
Return on Assets (ROA)
-38.62%
TTM Avg
-32.73%
3Y Avg
-28.05%
5Y Avg
-37.08%
Market Cap
$184.12M
Return on Assets (ROA)
-6.21%
TTM Avg
-15.18%
3Y Avg
-15.88%
5Y Avg
-16.43%
Market Cap
$162.82M
Return on Assets (ROA)
-50.30%
TTM Avg
-131.74%
3Y Avg
-92.52%
5Y Avg
-67.08%
Market Cap
$192.97M
Return on Assets (ROA)
-78.16%
TTM Avg
-23.70%
3Y Avg
-68.26%
5Y Avg
-50.80%
Market Cap
$153.84M
Return on Assets (ROA)
-90.55%
TTM Avg
-70.80%
3Y Avg
-45.07%
5Y Avg
-40.08%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | $176.96M | -534.43% | -94.69% | -82.47% | -71.30% |
| Canton Strategic Holdings Inc (CNTN)vs › | $179.70M | -17.38% | -167.34% | -136.62% | -286.91% |
| Precision BioSciences, Inc. (DTIL)vs › | $174.17M | -41.88% | -12.18% | -27.40% | -32.78% |
| Coherus Oncology, Inc. (CHRS)vs › | $173.04M | -68.50% | -29.78% | -39.51% | -30.76% |
| Compass Therapeutics, Inc. (CMPX)vs › | $172.99M | -38.62% | -32.73% | -28.05% | -37.08% |
| Journey Medical Corporation (DERM)vs › | $184.12M | -6.21% | -15.18% | -15.88% | -16.43% |
| ALX Oncology Holdings Inc. (ALXO)vs › | $162.82M | -50.30% | -131.74% | -92.52% | -67.08% |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $192.97M | -78.16% | -23.70% | -68.26% | -50.80% |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $153.84M | -90.55% | -70.80% | -45.07% | -40.08% |
| Anavex Life Sciences Corp. (AVXL)vs › | $152.45M | -20.01% | -38.20% | -34.64% | -39.69% |
ROA
-534.4%
ROE
-7104.2%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -63.02% |
| 2024-12-31 | -126.35% |
| 2023-12-31 | -82.45% |
| 2022-12-31 | -58.07% |
| 2021-12-31 | -52.95% |
| 2020-12-31 | -44.99% |
| 2019-12-31 | -51.25% |
| 2018-12-31 | -85.93% |
| 2017-12-31 | -34.70% |
| 2016-12-31 | -47.05% |
| 2015-12-31 | -26.37% |
